CMS proposes faster prior-authorization decisions for drugs

Patients in some CMS-regulated health plans could see faster prior-authorization decisions for prescription drugs if a new federal proposal is finalized. CMS says the rule would also push more plans toward electronic prior authorization, with the goal of reducing delays, paperwork, and unclear denials.

The proposal is not a blanket change for every insurer in the country. It would apply to specific CMS-regulated plan types, and it would still leave prior authorization in place.

What CMS is proposing

In its fact sheet and press release, CMS said the proposed rule would set shorter decision deadlines for drug prior authorization: no later than 24 hours for urgent requests and 72 hours for standard requests. The agency also says plans would need to increase transparency by publicly reporting more data on denials, appeals, and decision timelines.

CMS is also proposing broader electronic prior authorization requirements so requests and supporting information can move through more standardized digital systems instead of fax-heavy, manual workflows.

Who would be covered

CMS says the proposal would affect Medicare Advantage plans, Medicaid and CHIP managed care, ACA Marketplace plans on the federal exchange, and small group Marketplace plans on the federal SHOP exchange. It would not automatically apply to all private insurance plans.

That matters because prior authorization rules still vary by plan type, state, and benefit design.

Why this matters for patients

Prior authorization can slow access to medicines, especially for people who take long-term drugs or need treatment started quickly. KFF said in April 2026 that current prior-authorization data give only limited insight into what gets approved or denied, and the reporting does not include enough detail to fully explain why requests were rejected.

A recent JAMA Health Forum study published in April 2026 found that prior authorization can delay access after an initial rejection and that some prescriptions eventually get approved only after additional review. That kind of delay can matter for patients whose symptoms may worsen if treatment is pushed back.

What this would not do

The proposal would not eliminate prior authorization. It would not guarantee approval. And it would not instantly change every plan, because the rule still has to move through the federal process before any compliance deadlines take effect.

What readers should watch next

The main next step is whether CMS finalizes the rule and what final dates it sets for compliance. If finalized, the details will matter: which plans must comply, what counts as an urgent request, and how much information plans must publish about denials and appeals.

What readers can do now

If you or a family member relies on a medicine that often needs prior authorization, keep asking the plan and pharmacy whether the request has been submitted, whether it was marked urgent, and what documentation is still needed. If a medicine is delayed, ask the clinician’s office or pharmacy about the appeal process and whether a temporary alternative is available.

If symptoms are worsening because a medication has been delayed, seek prompt medical advice. For chest pain, trouble breathing, confusion, severe weakness, or other emergency symptoms, call 911 or go to the nearest emergency department.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.